Soligenix advances COVID-19 vaccine

By The Science Advisory Board staff writers

July 28, 2020 -- Biopharmaceutical firm Soligenix said that preclinical immunogenicity studies of its CiVax heat stable subunit COVID-19 vaccine candidate demonstrated that both broad-spectrum antibody immunity and cell-mediated rapid onset immunity are possible using the CoVaccine HT adjuvant.

Authored by collaborators from the University of Hawaiʻi at Mānoa, the article has been submitted to npj Vaccines for peer review. A manuscript preprint is available at bioRxiv.org.


Copyright © 2020 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?